| Outcome Measures: |
Primary: Pharmacokinetics parameters of INS068 and SHR20004: Cmax, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf, Based on pre-dose, 2-96 hours post-dose sampling times | Secondary: Pharmacokinetics parameters of INS068 and SHR20004: Tmax, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: T1/2, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: CL/F, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: Vz/F, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: Ae, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: fe, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: CLr, Based on pre-dose, 2-96 hours post-dose sampling times|Average concentrations of INS068 and SHR20004 in dialysate of ESRD, 0- 4 hours post-dose sampling times|Cumulative collection amount of INS068 and SHR20004 in dialysate of ESRD, 0- 4 hours post-dose sampling times|Dialysis clearance of INS068 and SHR20004 in dialysate of ESRD, 0- 4 hours post-dose sampling times|Binding rate of plasma protein of INS068 in serum and SHR20004 in plasma(fu), Based on pre-dose, 2-96 hours post-dose sampling times|The incidence and severity of adverse events/serious adverse events, Based on pre-dose, 2-96 hours post-dose sampling times|ADA：anti-drug antibody, Based on pre-dose、Day 5、Day14、Day 24 or early termination
|
